Therapix Biosciences Ltd.
TRPX
TRPX was delisted on the 1st of July, 2020.
4 hedge funds and large institutions have $42K invested in Therapix Biosciences Ltd. in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
33% less funds holding
Funds holding: 6 → 4 (-2)
55% less capital invested
Capital invested by funds: $93K → $42K (-$51K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.13K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
+$454 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$23K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $39K | +$2.13K | +470 | +5% |
|
|
2
UBS Group
Zurich,
Switzerland
| $2K | -$11K | -2,427 | -84% |
|
|
IA
3
IFP Advisors
Tampa,
Florida
| $1K | +$454 | +100 | +111% |
|
|
4
Acadian Asset Management
Boston,
Massachusetts
| – | -$23K | -4,100 | Closed |
|
TRPX Hedge Fund Activity: Q2 2018 in Review
4 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Therapix Biosciences Ltd. (TRPX) for Q2 2018, worth a combined $42K — down 55% from $93K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of TRPX and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Morgan Stanley, adding an estimated $2.13K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $23K sold.
- 4 institutional investors held Therapix Biosciences Ltd. (TRPX) as of Q2 2018, down from 6 in Q1 2018.
- Funds reported $42K of Therapix Biosciences Ltd. stock for Q2 2018, down 55% quarter-over-quarter.
- 0 funds opened new Therapix Biosciences Ltd. positions in Q2 2018 and 2 closed out, a net change of -2 holders.
- The largest Therapix Biosciences Ltd. buyer in Q2 2018 was Morgan Stanley, an estimated $2.13K added.
- The largest Therapix Biosciences Ltd. seller in Q2 2018 was Acadian Asset Management, an estimated $23K sold.
Based on aggregated 13F filings for Q2 2018.